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Two early-acting components of the cellular ESCRT
pathway, ESCRT-I and ALIX, participate directly in
HIV-1 budding. The membrane fission activities of
ESCRT-III subunits are also presumably required,
but humans express 11 different CHMP/ESCRT-III
proteins whose functional contributions are not yet
clear. We therefore depleted cells of each of the
different CHMP proteins and protein families and
examined the effects on HIV-1 budding. Virus release
was profoundly inhibited by codepletion of either
CHMP2 or CHMP4 family members, resulting in
R100-fold titer reductions. CHMP2A and CHMP4B
proteins bound one another, and this interaction
was required for budding. By contrast, virus release
was reduced only modestly by depletion of CHMP3
and CHMP1 proteins (2- to 8-fold titer reductions)
and was unaffected by depletion of other human
ESCRT-III proteins. HIV-1 budding therefore requires
only a subset of the known human ESCRT-III
proteins, with the CHMP2 and CHMP4 families play-
ing key functional roles.
INTRODUCTION
The ESCRT pathway mediates membrane fission in several
important biological processes, including intralumenal vesicle
formation at the multivesicular body (MVB), abscission during
cytokinesis, and budding of enveloped viruses from the plasma
membrane (for recent reviews, see Bieniasz, 2009; Hurley, 2010;
Hurley and Hanson, 2010; Raiborg and Stenmark, 2009; Sak-
sena and Emr, 2009). In each case, the ESCRT machinery func-
tions from the cytoplasmic face of the bilayer and draws the
closing membrane neck toward itself. This ability to catalyze
‘‘reverse topology’’ membrane fission events appears to explain
why many enveloped viruses, including HIV-1, have evolved to
usurp the cellular ESCRT machinery to bud from cells.
Although the proteins and complexes of the ESCRT pathway
must work together, they are recruited sequentially and perform
distinct functions. Early-acting factors such as ESCRT-I and
ALIX recognize and help remodel the appropriate membranes,
concentrate vesicular cargoes, and recruit the later-acting
factors (Hurley, 2010). Proteins of the ESCRT-III complex, in
turn, help mediate membrane fission and recruit the terminal
VPS4 ATPase complex. VPS4 then completes the cycle by usingCell Hothe energy of ATP hydrolysis to remove the assembled ESCRT
machinery from the membrane (Babst et al., 1998; Hurley and
Hanson, 2010; Wollert et al., 2009).
The mechanism of membrane fission is not yet understood in
detail, but current models hold that the soluble ESCRT-III
proteins are deposited within the necks of budding particles,
where they polymerize into filaments that spiral closed to form
a ‘‘dome’’ that draws the opposing membranes together (Fabri-
kant et al., 2009; Hurley and Hanson, 2010). ESCRT-III proteins
share a common helical core domain comprised of an extended
helical hairpin and two shorter helices that pack at the open end
of the hairpin. ESCRT-III proteins can adopt ‘‘closed’’ and
‘‘open’’ configurations, in which their extended C termini either
fold back on the core to autoinhibit polymerization (closed
conformation) or extend to allow core polymerization and
expose binding sites for VPS4, ALIX, and other proteins (open
conformation) (Bajorek et al., 2009b; Lata et al., 2008; Muzio1
et al., 2006; Shim et al., 2007).
ESCRT-III proteins can be divided into different families based
onprimary sequence similarities (see Figure S1).Saccharomyces
cerevisiae expresses four essential ESCRT-III proteins and three
‘‘regulatory’’ ESCRT-III-like proteins that function primarily in
Vps4p recruitment and regulation (Babst et al., 2002; Hurley,
2010; Saksena and Emr, 2009). The four essential ESCRT-III
proteins are recruited sequentially, in the following order (with
human protein names in parentheses). First, two Vps20p
(CHMP6) subunits appear to nucleate the assembly of two
spiraling Vps32p/Snf7p (CHMP4A-C) filaments within the bud
necks (Teis et al., 2010). These filaments are then capped by
Vps24p (CHMP3) and Vps2p (CHMP2A-B). Vps24p is required
to complete membrane fission, and Vps2p recruits Vps4p (Babst
et al., 2002; Hurley and Hanson, 2010; Saksena and Emr, 2009;
Wollert et al., 2009). Hence, all four essential yeast ESCRT-III
proteins are required for ESCRT-mediated fission.
Humans express at least 12 ESCRT-III-like proteins (termed
CHMP1-7 and IST1 [see Figure S1]) that can be grouped into
seven families corresponding to each of the seven different yeast
ESCRT-III proteins, plus an additional protein, CHMP7, not
found in yeast. Although their functional roles in virus budding
are not yet well defined, many ESCRT-III proteins can potently
inhibit virus budding when overexpressed as fusion proteins
(Martin-Serrano et al., 2003; Strack et al., 2003; von Schwedler
et al., 2003) or as truncations that remove the C-terminal autoin-
hibitory region (Zamborlini et al., 2006). However, CHMP6
fusions do not inhibit virus budding (Martin-Serrano et al.,
2003; von Schwedler et al., 2003), and HIV-1 can reportedly
bud efficiently from cells that lack IST1 (Agromayor et al.,
2009; Bajorek et al., 2009a), CHMP5 (Ward et al., 2005), or
CHMP6 (Langelier et al., 2006). Here, we have systematicallyst & Microbe 9, 235–242, March 17, 2011 ª2011 Elsevier Inc. 235
Figure 1. HIV-1 Release and Infectivity Can Be Modestly Affected by
Depletion of Individual ESCRT-III Proteins
Viral titers produced by cells expressing HIV-1 and treated with control siRNAs
(panel 1, lanes 1 and 2), with siRNAs that targeted TSG101 (positive control,
lane 3), or with the designated ESCRT-III proteins (lanes 4–14) (n = 6 titer
measurements from two independent experiments ± SD). Lower western
blots show virion-associated viral Gag proteins released into the supernatant
(panel 2, ‘‘Virus,’’ anti-CA and anti-MA), intracellular viral Gag protein
levels (panel 3, ‘‘Cell,’’ anti-CA and anti-MA), endogenous cellular ESCRT
proteins (panels 4–14), or a-Tubulin (panel 15, loading controls). See also
Figure S1.
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CHMP proteins and families in HIV-1 budding and thereby deter-
mined their redundancy and functional importance.
RESULTS
Requirements for Individual ESCRT-III Proteins
in HIV-1 Budding
We depleted each of the 11 different human CHMP proteins and
observed the effects on HIV-1 release and infectivity. A 12th
human ESCRT-III protein family member, IST1, was omitted,
because it has been shown to be dispensable for HIV-1 budding
(Agromayor et al., 2009; Bajorek et al., 2009a). Effects on HIV-1
release and infectivity were tested using at least two different
siRNAs that targeted each CHMP protein (Morita et al., 2010).
The data were consistent in all cases, and data for a single siRNA
are therefore typically reported. Each siRNA was shown to
deplete the endogenous target CHMP protein efficiently (Fig-
ure 1, lanes 4–14, panels 5–14) (Morita et al., 2010), with the
exception of siRNA targeting CHMP4C, which were validated
by demonstrating efficient depletion of an exogenously ex-
pressed, epitope-tagged protein, because suitable antibodies
were not available (Morita et al., 2010). Two irrelevant siRNA
constructs were used as negative controls (lanes 1 and 2), and
an siRNA against the essential budding factor, TSG101, was
used as a positive control (lane 3).
To analyze effects on HIV-1 release, infectious proviral expres-
sion constructs were cotransfected into siRNA-treated HEK293T
cells. Viral proteins were allowed to accumulate for 48 hr, and
then viral titers (panel 1) and levels of virion-associated viral CA
and MA proteins released into the media (panel 2) were
measured. As expected, TSG101 depletion strongly inhibited
viral infectivity (76-fold reduction in infectivity versus control
siRNA treatments) (Figure 1, panel 1) and virion release (panel
2, see virus-associated CA andMA protein levels in lane 3 versus
lanes 1 and 2). By contrast, HIV-1 release was not dramatically
affected by depletion of most individual ESCRT-III proteins,
although moderate reductions were observed in several cases.
The strongest reduction occurred upon depletion of CHMP4B,
which reduced virion release and infectivity 12-fold without
altering intracellular Gag, CA, or MA protein levels (panel 3,
compare lane 10 to lanes 1 and 2). The next greatest effect
was seen upon depletion of CHMP1B, which reduced viral titers
8-fold. However, CHMP1B depletion also diminished cellular
Gag, CA, and MA protein levels slightly, which could have
contributed to the reduction in virus release and infectivity
(panel 3, compare lane 5 to lanes 1 and 2). Depletion of CHMP2A,
CHMP2B, and CHMP1A caused modest reductions in virus
release and infectivity (4-, 2-, and 2-fold reductions, respec-
tively), and virus release was not appreciably diminished by
depletion of any of the other ESCRT-III proteins. Thus, depletion
of individual ESCRT-III proteins, particularly CHMP4B, can
inhibit virus release, but the effects are much weaker than for
depletion of the essential virus budding factor TSG101.
The CHMP2 and CHMP4 Families Are Required
for HIV-1 Budding
We next tested the possibility that the modest phenotypes seen
in our initial survey might reflect functional redundancy within236 Cell Host & Microbe 9, 235–242, March 17, 2011 ª2011 Elsevier Inc.
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Figure 2. CHMP2 and CHMP4 Protein Families Are Required for HIV-1 Release and Infectivity
(A and B) Viral titers, virion-associated Gag proteins, and intracellular protein levels in 293T cells expressing HIV-1 and depleted or codepleted of the designated
CHMP2 (A) or CHMP4 (B) family members. Figure panels are equivalent to those shown in Figure 1 (n = 3 titer measurements ± SD).
(C and D) Thin-sectioned transmission electron micrographs of arrested HIV-1 budding particles in cells lacking CHMP2A/B (C) or CHMP4A/B (D). Scale bars
are 100 nm.
(E) Quantification of arrested budding particles without (gray) or with (black) visible striations within their necks (see arrows in Figure 2C for examples).
See also Figure S2.
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effects of simultaneously depleting multiple proteins within
each family: CHMP1 (CHMP1A and 1B), CHMP2 (CHMP2A
and 2B), and CHMP4 (CHMP4A, 4B, and 4C). Codepletion of
CHMP1A and CHMP1B reduced virus release and infectivity
only modestly (2-fold) (Figure S2, compare lane 6 to lanes 1
and 2). Thus, CHMP1 family members may participate in virus
budding, but are not absolutely essential.
Codepletion of either CHMP2A and CHMP2B or CHMP4A,
CHMP4B, and CHMP4C resulted in dramatic reductions in HIV-1
release and infectivity (95- and 166-fold, respectively) (Figure 2A,
compare lane 6 to lanes 1 and 2, and Figure 2B, compare lane
10 to lanes 1 and 2). These data imply that individual CHMP2
and CHMP4 family members can function redundantly and that
HIV-1budding requires the presenceof at least oneCHMP2 family
member and at least one CHMP4 family member. For individual
CHMP4 family members, the relative functional importance (4B >
4A > 4C; compare lanes 5, 4, and 6, respectively) parallels their re-
ported cellular abundance (4B > 4A > 4C) (Katoh et al., 2004), with
CHMP4C making a negligible contribution to the phenotype.
CHMP2 and CHMP4 Are Required for Late Stages
of Virus Assembly
Thin-section transmission electron microscopic analyses
confirmed that partially budded virions accumulated at theCell Hoplasma membranes of cells that lacked either CHMP2A/B (Fig-
ure 2C) or CHMP4A/B (Figure 2D). In both cases, the virions
had immaturemorphologies and ranged from half shells to nearly
complete spheres. The two cases differed, however, in that ring-
like striations were sometimes visible in the necks of virions that
budded from cells that lacked CHMP2A/B (arrows in Figure 2C,
22% of late budding virions; see Figure 2E for quantification), but
rarely in cells that lacked CHMP4A/B (2% of budding virions).
CHMP3 Is Not Essential for HIV-1 Budding
During MVB vesicle formation in S. cerevisiae, the homolog of
CHMP3 (Vps24p) forms an essential bridge between Vps2p
(CHMP2) and Vps32p/Snf7p (CHMP4) (Babst et al., 2002; Wol-
lert et al., 2009). It was therefore surprising that depletion of
the only known human CHMP3 protein reduced virus release
and infectivity less than 2-fold (Figure 1, compare lane 8 to lanes
1 and 2). To confirm this result, we tested the effects of ten addi-
tional CHMP3 siRNA constructs. As shown in Figure S3, five
different siRNA constructs depleted endogenous CHMP3 very
efficiently (panel 4, compare lane 1 to lanes 2–6), but none had
major effects on virion release (panel 2) or viral titers (panel 1).
In two cases, viral titers were reduced 2- to 4-fold (siRNA
constructs 474 and 461), and in the other three cases the titers
changed less than 2-fold, whereas codepletion of either
CHMP2A/B or CHMP4A/B reduced viral titers more thanst & Microbe 9, 235–242, March 17, 2011 ª2011 Elsevier Inc. 237
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impair virus infectivity, release, and Gag processing slightly
(panel 3, compare the CA-SP1 bands in lanes 2–6 to lane 1),
but the effects were much weaker than depletion of the
CHMP2 or CHMP4 families.
Yeast Two-Hybrid Analyses of CHMP2:CHMP4
Interactions
The relative unimportance of CHMP3 in our virus release and
infectivity assays suggested that CHMP2:CHMP4 interactions
might bypass the functional requirement for CHMP3. We used
the yeast two-hybrid assay as a convenient method to screen
for possible CHMP2:CHMP4 interactions. As reported previ-
ously, we did not detect an interaction between the full-length
CHMP2A and CHMP4B proteins in either possible orientation
(Martin-Serrano et al., 2003; von Schwedler et al., 2003) (Fig-
ure 3A and data not shown), even though our CHMP4B and
CHMP2A constructs showed positive interactions with known
binding partners in control experiments (e.g., CHMP4B:
CHMP4B and VPS4A:CHMP2A). However, a construct that
lacked the C-terminal autoinhibitory region of CHMP2A
(CHMP2A1-146) did interact with CHMP4B in these assays. The
truncated CHMP2A1-146 construct also gained a CHMP1A inter-
action and lost the VPS4A interaction (because it lacked the
C-terminal VPS4A MIT domain binding site [Stuchell-Brereton
et al., 2007]). Thus, removing the CHMP2A C-terminal autoinhi-
bitory region promoted interactions with other ESCRT-III
proteins, consistent with previous reports (e.g., Lata et al.,
2008; Lin et al., 2005; Shim et al., 2007).
Homology models were used to guide the design of
surface alanine-scanning mutations for both CHMP2A1-146 (52
mutants) and CHMP4B (118 mutants) that might inhibit the
CHMP2A1-146:CHMP4B interaction while retaining other control
interactions. These analyses identified: (1) a triple point mutation
in three successive arginine residues on the exposed face of
CHMP2A1-146 helix 1 (R24R27R31 to AAA, termed CHMP2AC4)
that inhibited the interaction with CHMP4B but retained the
CHMP1A interaction (Figures 3A and 3B), and (2) a quadruple
point mutation on the exposed loop between helices 2 and 3 of
CHMP4B (EVLK104-107 to AAAA, termed CHMP4BC2) that in-
hibited the CHMP2A interaction but retained the CHMP4B
interaction (Figures 3A and 3B). Thus, we identified a truncated
CHMP2A construct that could interact with both CHMP4B
and CHMP1A and point mutations within either CHMP2A1-146
or CHMP4B that eliminated the CHMP2A1-146:CHMP4B
interaction.
Recombinant CHMP2A and CHMP4B Protein
Interactions
Overexpressed CHMP2A and CHMP4 proteins can be coimmu-
noprecipitated, indicating that these two proteins can interact
in cells (Martin-Serrano et al., 2003). However, such CHMP2A:
CHMP4 interactions may depend upon membrane binding
and/or other cellular proteins. We performed GST pull-down
experiments to test whether full-length recombinant CHMP2A
and CHMP4B proteins could interact specifically. As shown in
Figure 3C, pure recombinant CHMP2A protein bound weakly
but reproducibly to immobilized GST-CHMP4B and not to
a control matrix (compare lanes 2 and 5). Furthermore, the238 Cell Host & Microbe 9, 235–242, March 17, 2011 ª2011 Elseviersame CHMP2A mutation that inhibited CHMP4B binding in the
yeast two-hybrid experiments also inhibited CHMP2AC4
binding to GST-CHMP4B, demonstrating the specificity of this
interaction (compare lanes 5 and 6). Similarly, the GST-
CHMP4BC2 mutation blocked the binding of pure recombinant
CHMP2A protein (Figure 3D, compare lanes 4 and 6). Thus, re-
combinant full-length CHMP2A and CHMP4B proteins can
interact in vitro, and the CHMP2AC4 and CHMP4BC2 muta-
tions inhibit this interaction.
The CHMP2A:CHMP4B Interaction Is Required
for HIV-1 Budding
To examine the functional importance of the CHMP2A-CHMP4B
interaction, we tested whether point mutations that inhibited this
interaction also inhibited HIV-1 release and infectivity using
siRNA depletion and rescue assays. As expected, HIV-1 release
and infectivity were strongly inhibited by codepletion of
CHMP2A and CHMP2B (Figure 4A, panels 1 and 2, 167-fold
infectivity reduction, compare lanes 1 and 2). This inhibition
was substantially though not completely rescued by overexpres-
sion of either a wild-type, siRNA-resistant CHMP2A construct
(72-fold rescue, compare lanes 2 and 3) or a wild-type, siRNA-
resistant CHMP2B (data not shown). In contrast, mutant
CHMP2A constructs that could not bind either the VPS4
ATPases (CHMP2AVPS4) or CHMP4B (CHMP2AC4) were
unable to rescue the defects in virus infectivity, release, or Gag
processing (compare lanes 4 and 5 to lane 3), even though
both mutant proteins expressed normally (Figure 4A, panel 4).
Thus, CHMP2Amutations that inhibited VPS4 or CHMP4 binding
also impaired HIV-1 budding.
Analogous experiments were used to test the functional
importance of the CHMP2A binding site on CHMP4B. Codeple-
tion of CHMP4A and CHMP4B reduced viral infectivity 76-fold
(Figure 4B, compare lanes 1 and 2), and this defect was substan-
tially rescued by overexpression of an siRNA-resistant CHMP4B
protein (compare lanes 2 and 3, 40-fold infectivity rescue). In
contrast, CHMP4B mutants that could not bind ALIX
(CHMP4BALIX) or CHMP2A (CHMP4BC2) rescued virus
budding less well (22-fold and 7-fold, respectively; compare
lanes 4 and 5 to lane 3) and also failed to rescue the accumula-
tion of intracellular CA-SP1 processing intermediates (panel 3).
Thus, inactivating point mutations on either side of the
CHMP2A:CHMP4B interface inhibited HIV-1 budding.
DISCUSSION
We have shown that efficient HIV-1 budding requires at least one
member of both the CHMP2 andCHMP4 ESCRT-III protein fami-
lies, and different members of both families can function redun-
dantly. Viral infectivity and Gag processing were also modestly
inhibited by depletion of CHMP1 and CHMP3 proteins (Figures
1, S2, and S3), suggesting that these two ESCRT-III families
may also participate in HIV budding, but are not essential. By
contrast, virus budding proceeded efficiently in the absence of
CHMP5, CHMP6, CHMP7, and IST1 (Figure 1) (Agromayor
et al., 2009; Bajorek et al., 2009a; Langelier et al., 2006; Ward
et al., 2005). These results contrast with the requirements for
cytokinesis, where each human ESCRT-III protein, with the
possible exception of CHMP6, plays a significant functionalInc.
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Figure 3. Identification and Characterization of CHMP2A:CHMP4B Interactions
(A) Panel showing yeast two-hybrid interactions between the designated ESCRT proteins fused to activation (AD) or DNA binding (DBD) domains (or with empty
vector controls). The following interactions were judged to be positive (AD fusions listed first): CHMP1A:CHMP2A1-146, CHMP1A:CHMP2A1-146,C4-,
CHMP4B:CHMP2A1-146, CHMP4B:CHMP4B, CHMP4BC2:CHMP4B, VPS4A:CHMP2A. VPS4A also interacted very weakly with CHMP4B in this assay.
(B) Upper: homology model of CHMP2A showingmutations that blocked binding of CHMP4B (designated CHMP2AC4) or VPS4A and B (CHMP2AVPS4). Lower:
homology model of CHMP4B showing mutations that blocked binding of CHMP2A (CHMP4BC2) or ALIX (CHMP4BALIX). Homology models were generated by
threading the CHMP2A and CHMP4B sequences onto the known CHMP3 structure (PDB: 3FRT) (Bajorek et al., 2009b; Muzio1 et al., 2006) using SWISS-MODEL
(Arnold et al., 2006) and COOT (Emsley and Cowtan, 2004), and displayed using PyMOL (DeLano, 2008).
(C and D) GST pull-down analyses demonstrating that recombinant CHMP2A and CHMP4B proteins interact and that the mutations in the CHMP2AC4 (C) and
CHMP4BC2 (D) constructs inhibit these interactions. Shown in (C): SDS-PAGE/Coomassie detection of matrix-bound proteins following incubation of immobi-
lized GST (lanes 1–3, negative controls) or GST-CHMP4B proteins (lanes 4–6) with no added proteins (lanes 1 and 4, negative controls) or with purified wild-type
CHMP2A (lanes 2 and 5) or CHMP2AC4 (lanes 3 and 6) is shown. Input CHMP2A proteins are shown in lanes 7 and 8 (2% of total). Shown in (D): SDS-PAGE/
Coomassie detection of matrix-bound proteins following incubation of immobilized GST (lanes 1 and 2, negative controls), wild-type GST-CHMP4B (lanes 3 and
4), or GST-CHMP4BC2 (lanes 5 and 6) with no added proteins (lanes 1, 3, and 5) or with purified wild-type CHMP2A (lanes 2, 4, and 6) is also shown. Input
CHMP2A is shown in lane 7 (2% of total). See also Figure S3.
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only a subset of the known human ESCRT-III proteins and
functions.
siRNA Depletion Experiments
As in all siRNA depletion experiments, negative or weak budding
phenotypes could have reflected insufficient protein depletion
and/or functional redundancy. However, our siRNA protocols
depleted CHMP1A, CHMP1B, CHMP3, and CHMP5-7 suffi-
ciently to induce cell division defects (Morita et al., 2010), and
multiple different siRNAs that efficiently depleted CHMP3 all
failed to substantially inhibit HIV-1 budding (Figure S3). Further-
more, we tested all possible pairwise knockdowns of CHMP1A,
CHMP1B, CHMP3, and CHMP5-7 and did not observe syner-
gistic inhibition of HIV-1 budding in any case (Figure S2 andCell Hodata not shown). We conclude that none of these proteins func-
tion redundantly or provide critical functions in HIV-1 budding.
The strong budding defects induced by depletion of endoge-
nous CHMP2A/B or CHMP4A/B were substantially rescued by
expression of exogenous, siRNA-resistant CHMP2A, CHMP2B,
and CHMP4B proteins, ruling out off-target effects (Figure 4 and
data not shown). Furthermore, point mutations that abrogated
the CHMP2A:VPS4, CHMP2A:CHMP4B, and CHMP4:ALIX
interactions also inhibited virus budding, indicating that each of
these interactions is functionally significant. Although it remains
possible that sequestration of ESCRT factors on endosomal
membranes could have contributed indirectly to the observed
budding defects, our siRNA depletion experiments are the
most direct functional tests of ESCRT-III protein requirements
in HIV-1 budding reported to date. Indeed, it appears likelyst & Microbe 9, 235–242, March 17, 2011 ª2011 Elsevier Inc. 239
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Figure 4. Point Mutations that Inhibit CHMP2A-CHMP4B Interac-
tions also Block HIV-1 Budding
(A) Viral titers, virion-associated Gag proteins, and intracellular protein levels
in 293T cells expressing HIV-1 (lanes 1–5) and treated with a control siRNA
(lane 1) or with siRNAs that codepleted CHMP2A/B (lanes 2–5), together
with an empty control vector (lane 2) or with vectors expressing siRNA-resis-
tant wild-type CHMP2A (lane 3), CHMP2AVPS4 (lane 4), or CHMP2AC4
(lane 5). Figure panels are equivalent to those in Figures 1 and 2 (n = 9 titer
measurements from three independent experiments ± SD).
(B) This experiment is equivalent to (A), except that cells were codepleted of
CHMP4A/B (lanes 2–5) and the siRNA-resistant rescue constructs expressed
wild-type CHMP4B (lane 3), CHMP4BALIX (lane 4), or CHMP4BC2 (lane 5)
(n = 6–12 titer measurements from 2–4 independent experiments ± SD).
See also Figure S4.
Cell Host & Microbe
ESCRT-III Protein Requirements for HIV-1 Buddingthat the dominant inhibition of HIV-1 budding reported previously
for overexpression of CHMP3 and several other ESCRT-III
constructs may have resulted from indirect sequestration or
inactivation of CHMP2, CHMP4, and/or other ESCRT factors,
rather than from the direct loss of critical budding activities
(Martin-Serrano et al., 2003; Strack et al., 2003; von Schwedler
et al., 2003; Zamborlini et al., 2006).
Comparisons to Yeast MVB Vesicle Formation
Yeast MVB vesicle formation serves as an important paradigm
for understanding ESCRT-III assembly and function (Hurley
and Hanson, 2010; Saksena and Emr, 2009). However, we
have demonstrated that the ESCRT-III requirements for yeast
MVB vesicle formation andHIV-1 budding differ in several impor-
tant ways. First, human CHMP3 is dispensable for HIV budding,
whereas yeast Vps24p (CHMP3) provides a critical link between240 Cell Host & Microbe 9, 235–242, March 17, 2011 ª2011 ElsevierVps2p (CHMP2) and Snf7p (CHMP4) (Babst et al., 2002; Wollert
et al., 2009), both in vivo and in a reconstituted yeastMVB vesicle
system (Wollert et al., 2009). We found instead that human
CHMP2 and CHMP4 can interact, which apparently obviates
the strict requirement for a bridging CHMP3 protein. Thus,
although CHMP2A/CHMP3 complexes can coassemble into
helical domes in vitro (Bajorek et al., 2009b; Lata et al., 2008),
CHMP3 does not appear to be an obligate CHMP2 binding
partner during HIV budding.
Second, HIV budding efficiency was unaltered by CHMP6
depletion (Figures 1 and S4). We have previously reported that
ESCRT-II, a protein complex that can recruit CHMP6, is also
dispensable for HIV-1 budding (Langelier et al., 2006). This situ-
ation again differs from yeast MVB formation, where the ESCRT-
II/Vps20 (CHMP6) interaction is required to nucleate Snf7p
(CHMP4) assembly (Teis et al., 2010). Thus, HIV-1 virions and
yeast MVB vesicles must initiate ESCRT-III recruitment and
assembly using fundamentally different sets of protein-protein
interactions.
ESCRT-III Protein Recruitment
We cannot yet fully explain the mechanisms by which HIV-1
recruits ESCRT-III proteins to sites of virus budding. The inter-
mediate activity of the CHMP4BALIX protein implies that the
CHMP4B:ALIX interaction contributes to the efficiency of HIV-1
budding but is not absolutely required (Figure 4B). Similarly,
depleting ALIX from 293T cells (or mutating the ALIX binding
site within p6Gag) typically reduces viral infectivity 2-fold (e.g.,
Fujii et al., 2009) (Figure S4, compare lanes 1 and 2). These
observations all indicate that ALIX contributes to but is not abso-
lutely essential for HIV-1 budding under conditions where p6Gag
can also bind TSG101/ESCRT-I.
The critical importance of the CHMP2 and CHMP4 protein
families implies that ESCRT-I can recruit these two ESCRT-III
protein families independently of ALIX. We hypothesized that
sequential interactions between ESCRT-I, ESCRT-II, and
CHMP6 might serve to recruit CHMP4 proteins, by analogy to
the well-established sequential recruitment steps during yeast
MVB formation. This model was attractive because human
ESCRT-I:II, ESCRT-II:CHMP6, and CHMP6:CHMP4 interactions
have all been documented (e.g., Langelier et al., 2006; Martin-
Serrano et al., 2003; von Schwedler et al., 2003) and because
redundant pathways for CHMP4 recruitment (i.e., via p6Gag:ALIX
or via p6Gag:ESCRT-I:ESCRT-II:CHMP6) could, in principle,
explain why HIV-1 can still bud from cells that lack ESCRT-II,
CHMP6, or ALIX. However, codepletion of CHMP6 did not
further exacerbate the 2-fold reduction in virus release and infec-
tivity seen for depletion of ALIX alone (Figure S4). Thus, HIV-1
Gag and/or ESCRT-I appear to recruit CHMP4 using additional
protein-protein or protein-membrane interactions that remain
to be identified.
Minimal ESCRT-III Requirements for Efficient HIV-1
Budding
Although ESCRT-III protein activities and functions remain to be
characterized more fully, our data are consistent with a model in
which CHMP4 proteins form rings within the necks of budding
particles and recruit CHMP2 proteins, which in turn recruit the
VPS4 ATPases and promote membrane fission by helping toInc.
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ESCRT-III Protein Requirements for HIV-1 Buddingcreate dome-like structures that bring the opposing membranes
together (Fabrikant et al., 2009). Consistent with this model, we
frequently observed ring-like structures within the necks of
arrested particles that lacked CHMP2 (Figure 2); others have
shown that overexpressed CHMP4 proteins can form helical
plasma membrane protrusions (Hanson et al., 2008), and the
CHMP2 proteins contain binding sites for the MIT domains of
VPS4 proteins (Stuchell-Brereton et al., 2007). Thus, the ability
to assemble a constricting dome within the bud neck and to
recruit VPS4 ATPase(s) may represent the minimal activities
required for efficient HIV-1 budding.EXPERIMENTAL PROCEDURES
Cell Culture
293T and HeLa-TZM reporter cells were obtained from J.C. Kappes and X. Wu
through the AIDSResearch and Reference Reagent Program, Division of AIDS,
NIAID, NIH and maintained in DMEM supplemented with 10% FCS.siRNA and Expression Vectors
siRNAs were designed using the Dharmacon siDESIGNCenter (Thermo Fisher
Scientific, Inc.), selected as described in Morita et al. (2010), and listed in the
Supplemental Information along with expression vectors.HIV-1 Production from Cells Lacking ESCRT Proteins
siRNA depletion/reconstitution, virion production, and quantification proce-
dures have been described (Kieffer et al., 2008), and detailed protocols are
provided in the Supplemental Information.Yeast Two-Hybrid Experiments
Directed two-hybrid assays with human ESCRT genes were performed using
the Matchmaker GAL4 Yeast Two-Hybrid 3 system (Clontech). pGADT7 and
pGBKT7-based constructs (500 ng each, see Table S2) were cotransformed
into 10 ml of competent yeast strain PJ69-4A in the presence of 38 ml of 40%
PEG3350, 0.1 M lithium acetate, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA
(pH 8.0). Transformation efficiencies were tested on selective –Leu and -Trp
plates and two-hybrid interactions were tested on selective -Leu, -Trp, -Ade,
and -His plates.GST Pull-Down Experiments
Protocols for CHMP2A protein expression and purification and for GST
pull-down experiments are provided in the Supplemental Experimental
Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, and four figures and can be found with this article
online at doi:10.1016/j.chom.2011.02.004.ACKNOWLEDGMENTS
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